131 related articles for article (PubMed ID: 36610263)
1. ctDNA-Response evaluation criteria in solid tumors - a new measure in medical oncology.
Jakobsen AKM; Spindler KG
Eur J Cancer; 2023 Feb; 180():180-183. PubMed ID: 36610263
[TBL] [Abstract][Full Text] [Related]
2. Improving on-treatment risk stratification of cancer patients with refined response classification and integration of circulating tumor DNA kinetics.
Lv J; Wu C; Li J; Chen F; He S; He Q; Zhou G; Ma J; Sun Y; Wei D; Lin L
BMC Med; 2022 Aug; 20(1):268. PubMed ID: 35996151
[TBL] [Abstract][Full Text] [Related]
3. Circulating tumor DNA: Response Evaluation Criteria in Solid Tumors - can we RECIST? Focus on colorectal cancer.
Spindler KG; Jakobsen A
Ther Adv Med Oncol; 2023; 15():17588359231171580. PubMed ID: 37152423
[TBL] [Abstract][Full Text] [Related]
4. Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST).
Gouda MA; Janku F; Wahida A; Buschhorn L; Schneeweiss A; Abdel Karim N; De Miguel Perez D; Del Re M; Russo A; Curigliano G; Rolfo C; Subbiah V
Ann Oncol; 2024 Mar; 35(3):267-275. PubMed ID: 38145866
[TBL] [Abstract][Full Text] [Related]
5. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
[TBL] [Abstract][Full Text] [Related]
6. BESPOKE IO protocol: a multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumours.
Kasi PM; Chakrabarti S; Sawyer S; Krainock M; Poklepovic A; Ansstas G; Maninder M; Malhotra M; Ensor J; Gao L; Eroglu Z; Ellers S; Billings P; Rodriguez A; Aleshin A
BMJ Open; 2022 May; 12(5):e060342. PubMed ID: 35636789
[TBL] [Abstract][Full Text] [Related]
7. Early ctDNA response to chemotherapy. A potential surrogate marker for overall survival.
Jakobsen A; Andersen RF; Hansen TF; Jensen LH; Faaborg L; Steffensen KD; Thomsen CB; Wen SWC
Eur J Cancer; 2021 May; 149():128-133. PubMed ID: 33857886
[TBL] [Abstract][Full Text] [Related]
8. Regulatory implications of ctDNA in immuno-oncology for solid tumors.
Vellanki PJ; Ghosh S; Pathak A; Fusco MJ; Bloomquist EW; Tang S; Singh H; Philip R; Pazdur R; Beaver JA
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36796877
[TBL] [Abstract][Full Text] [Related]
9. Circulating tumour DNA is a potential biomarker for disease progression and response to targeted therapy in advanced thyroid cancer.
Allin DM; Shaikh R; Carter P; Thway K; Sharabiani MTA; Gonzales-de-Castro D; O'Leary B; Garcia-Murillas I; Bhide S; Hubank M; Harrington K; Kim D; Newbold K
Eur J Cancer; 2018 Nov; 103():165-175. PubMed ID: 30253333
[TBL] [Abstract][Full Text] [Related]
10. Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer.
Kruger S; Heinemann V; Ross C; Diehl F; Nagel D; Ormanns S; Liebmann S; Prinz-Bravin I; Westphalen CB; Haas M; Jung A; Kirchner T; von Bergwelt-Baildon M; Boeck S; Holdenrieder S
Ann Oncol; 2018 Dec; 29(12):2348-2355. PubMed ID: 30346475
[TBL] [Abstract][Full Text] [Related]
11. Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis.
Cullinane C; Fleming C; O'Leary DP; Hassan F; Kelly L; O'Sullivan MJ; Corrigan MA; Redmond HP
JAMA Netw Open; 2020 Nov; 3(11):e2026921. PubMed ID: 33211112
[TBL] [Abstract][Full Text] [Related]
12. Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies.
Lee JH; Long GV; Menzies AM; Lo S; Guminski A; Whitbourne K; Peranec M; Scolyer R; Kefford RF; Rizos H; Carlino MS
JAMA Oncol; 2018 May; 4(5):717-721. PubMed ID: 29423503
[TBL] [Abstract][Full Text] [Related]
13. The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA.
Liu B; Hu Z; Ran J; Xie N; Tian C; Tang Y; Ouyang Q
Breast; 2022 Oct; 65():116-123. PubMed ID: 35926241
[TBL] [Abstract][Full Text] [Related]
14. Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma.
Pal SK; Sonpavde G; Agarwal N; Vogelzang NJ; Srinivas S; Haas NB; Signoretti S; McGregor BA; Jones J; Lanman RB; Banks KC; Choueiri TK
Eur Urol; 2017 Oct; 72(4):557-564. PubMed ID: 28413127
[TBL] [Abstract][Full Text] [Related]
15. Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study.
Pécuchet N; Zonta E; Didelot A; Combe P; Thibault C; Gibault L; Lours C; Rozenholc Y; Taly V; Laurent-Puig P; Blons H; Fabre E
PLoS Med; 2016 Dec; 13(12):e1002199. PubMed ID: 28027313
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer; a systematic review and meta-analysis.
Jones RP; Pugh SA; Graham J; Primrose JN; Barriuso J
Eur J Cancer; 2021 Feb; 144():368-381. PubMed ID: 33422803
[TBL] [Abstract][Full Text] [Related]
17. A perspective: the integration of ctDNA into Response Evaluation Criteria in Solid Tumours 1.1 for phase II immunotherapy clinical trials.
Kus T; Cicin I
Immunotherapy; 2024 Mar; 16(5):319-329. PubMed ID: 38197142
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Solid Tumor Treatment Response Observed in Clinical Practice With Response Reported in Clinical Trials.
Feinberg BA; Zettler ME; Klink AJ; Lee CH; Gajra A; Kish JK
JAMA Netw Open; 2021 Feb; 4(2):e2036741. PubMed ID: 33630085
[TBL] [Abstract][Full Text] [Related]
19. Incorporating circulating tumor DNA detection to radiographic assessment for treatment response in advanced EGFR-mutant lung cancer.
Kok PS; Lee K; Lord S; John T; Marschner I; Wu YL; Mok TSK; Lee CK
Lung Cancer; 2022 Jan; 163():14-18. PubMed ID: 34894454
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumor DNA: current challenges for clinical utility.
Dang DK; Park BH
J Clin Invest; 2022 Jun; 132(12):. PubMed ID: 35703177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]